Overcoming obstacles in Cancer Treatment

for years, scientists have struggled to develop effective drugs that can block transcription factors, proteins that play a pivotal role in regulating gene expression and, consequently, cancer development.Traditional approaches have often fallen short. However, researchers at the university of Bath in England have pioneered a novel screening technology that identifies peptides capable of irreversibly deactivating a key protein involved in cancer, offering a potential solution to this long-standing challenge.

Irreversible peptide Inhibitors: A New Weapon Against Cancer

The research team has successfully developed the first irreversible peptide inhibitors that target and block the CJJ protein, a critical factor in cancer progression. This breakthrough was achieved using a cutting-edge screening method that allows for the identification of effective molecules within cells, a feat previously deemed unfeasible.

Transcription Blocks (TBS) Assay: A Revolutionary Drug Discovery Platform

The findings, published in the esteemed journal Advanced Science, are based on an innovative drug discovery platform known as the Transcription Blocks (TBS) Assay. This platform enables researchers to screen a vast number of peptides to pinpoint those capable of “disabling” transcription factors implicated in cancer. This high-throughput screening approach substantially accelerates the identification of potential drug candidates.

“Many candidate molecules for drug status prove toxic or unable to penetrate cancer cells. But our platform allows the activity of peptides directly inside the cell, avoiding the many obstacles associated with medicines based on small molecules or antibodies,”

Professor jody mason, a specialist in Bath and Scientific Director. Therapeutics.

From Reversible to Irreversible: A Significant leap Forward

While the research team had previously identified reversible inhibitors of the CJUD protein, this new study marks a significant advancement with the discovery of peptides that bind irreversibly to the protein, effectively blocking it permanently. This irreversible binding is crucial for sustained therapeutic affect.

How the Inhibitor works: A Molecular Harpoon

The CJUD protein consists of two identical halves that bind to DNA,influencing gene expression. In cancer, CJUD can become hyperactive, contributing to uncontrolled cell growth. The researchers designed a peptide inhibitor that attaches to one half of the CJUD protein, preventing it from forming pairs and binding to DNA, thus disrupting its function.

“The inhibitor works like a harpoon that is attached to the target and does not release-it is firmly linked to CJJ and prevents it from interacting with the DNA. In the past, we have discovered reversible inhibitors, but this is the first peptide inhibitor that irreversibly blocks a transcript factor,”

Dr. Andy Brennan,Life sciences of Bath University.

Following the creation of an inhibitor that binds to the transcription factor, the researchers modified it to ensure irreversible binding to cancer cells, maximizing its therapeutic potential.

TBS Assay: Ensuring Efficacy and Safety

The TBS assay plays a crucial role in ensuring both the efficacy and safety of the identified peptide inhibitors. In these tests, researchers introduce specific DNA sequences for CJun, a protein similar to CJUD, into essential genes of cells grown in the laboratory. When CJun binds to this gene, it disrupts normal cell function, leading to cell death. However, if CJun is blocked by the peptide inhibitor, gene activity is restored, and the cells survive. This process allows researchers to identify non-toxic peptides that effectively target the desired protein.

This method verifies the inhibitor’s functionality within a realistic cellular habitat, were othre proteins could perhaps interfere with its activity, while simultaneously assessing its toxicity.

The Future of Cancer Treatment: Targeting the “Undruggable”

The researchers are optimistic that this technology will pave the way for the discovery of new treatment options for various cancers, including those involving proteins that were previously considered “undruggable.” The ability to selectively and irreversibly inhibit these proteins represents a significant step forward in cancer therapy.

Having demonstrated the ability of these inhibitors to enter cancer cells and selectively act on their targets, the research team is now preparing to evaluate their effectiveness in preclinical cancer models. This next phase of research will be crucial in determining the potential of these peptide inhibitors as a viable cancer treatment.